Vendor scorecard

Ro

70/100
Routable
United States · Telehealth (50 states) · US-direct telehealth · FDA-approved GLP-1 formulary including Zepbound vials (LillyDirect / Gifthealth integration) + Foundayo oral (April 9, 2026 launch) + brand semaglutide

Ro scored 70/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.

Visit Ro →Read the rubricGet your match
11-signal breakdown
  • COA on every lot
    Brand pharmacy supply only · per-batch QC handled at manufacturer level (Lilly / Novo)
    85
  • Cold-chain verified
    Brand-pharmacy distribution; LillyDirect + Gifthealth handle cold-chain to home
    80
  • Rx legality
    FDA-approved formulary across the entire GLP-1 lineup · no compounded exposure to the April 30 503B-exclusion proposal
    90
  • Compound identity
    Lilly-partner branded supply · identity at manufacturer assurance level
    85
  • Dose accuracy
    85
  • Endotoxin testing
    Brand manufacturing standards
    80
  • Refund posture
    70
  • Channel clarity
    FDA-approved-only formulary; insurance + cash-pay both supported. Foundayo at $149/mo cash from April 2026 launch
    90
  • Support quality
    Insurance Checker + ~2M users helped with benefits coverage as of 2026
    75
  • Price transparency
    Cash + insurance options published; membership + medication fee structure visible pre-checkout
    75
  • Longitudinal retention
    Cleanest pivot in the US telehealth GLP-1 cohort; brand-only formulary + Lilly partnership de-risks the 503B-exclusion final-rule overhang
    70
Supply where Ro operates
Mounjaro
Stable

Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.

0d ago
Ozempic
Stable

Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.

1w ago
Rybelsus
Stable

Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.

1w ago
Wegovy
Stable

Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.

0d ago
Zepbound
Stable

Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.

0d ago
Full supply tracker across all regions →
Sources we audited against
How we score

The 11-signal rubric is public.

Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.

If Ro wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.

Full methodology →

Want a match for your situation?

Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.

Take the quiz

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.